adavosertib
adavosertib: 6 clinical trials tracked.
adavosertib evidence translation
What we can confirm
6 tracked trials
What it means
What to watch
Prepared research question
What is verified about adavosertib, and what remains unknown?
Traceable citations · Unknowns marked
See linked entities and source evidence8 indications · 1 study sponsors
Clinical Trial Registry Records (6)
EFFORT: Efficacy of AZD1775 in Parp Resistance; A Randomized 2-Arm, Non-Comparative Phase 2 Study of AZD1775 Alone or AZD1775 and Olaparib in Women With Ovarian Cancer Who Have Progressed During PARP Inhibition
Primary endpoint: Objective response rate
A Phase 2 Study of the Wee1 Inhibitor AZD1775 in Women With Recurrent or Persistent Uterine Serous Carcinoma or Uterine Carcinosarcoma
Primary endpoint: Objective response rate
An Open-Label, Randomised, Multi-Drug, Biomarker-Directed, Multi-Centre, Multi-arm Phase 1b Study in Patients With Muscle Invasive Bladder Cancer (MIBC) Who Have Progressed on Prior Treatment (BISCAY).
Primary endpoint: Module A: The frequency and nature of adverse events related to AZD4547 monotherapy.
A Phase I Study Assessing the Safety, Tolerability and Pharmacokinetics of AZD1775 (Adavosertib) in Combination With MEDI4736 (Durvalumab) in Patients With Advanced Solid Tumours
Primary endpoint: The incidence of Dose Limiting Toxicities (DLTs)
A Phase II Trial of AZD1775 Plus Carboplatin-Paclitaxel in Squamous Cell Lung Cancer
Primary endpoint: Progression Free Survival (PFS)
Molecular Analysis for Therapy Choice (MATCH)
Primary endpoint: Objective response rate (ORR)